Cytosorbents Corp CTSO

NAS: CTSO | ISIN: US23283X2062   26/04/2024
0,819 USD (+1,24%)
(+1,24%)   26/04/2024

14 augustus 2023 · CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial · Persbericht

27 februari 2023 · CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference · Persbericht

24 februari 2023 · CytoSorbents to Report Fiscal 2022 Operating and Financial Results · Persbericht

31 januari 2023 · CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue · Persbericht

23 januari 2023 · CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial · Persbericht

17 januari 2023 · CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs · Persbericht

29 december 2022 · CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement · Persbericht

21 december 2022 · CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications · Persbericht

14 november 2022 · CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled · Persbericht

3 november 2022 · CytoSorbents Reports Third Quarter 2022 Financial and Operational Results · Persbericht

2 november 2022 · 'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals · Persbericht

31 oktober 2022 · National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma · Persbericht

27 oktober 2022 · CytoSorbents to Report Third Quarter 2022 Operating and Financial Results · Persbericht

12 oktober 2022 · CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting · Persbericht

7 oktober 2022 · CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch · Persbericht

6 oktober 2022 · CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma · Persbericht

4 oktober 2022 · CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference · Persbericht

27 september 2022 · CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey · Persbericht

9 september 2022 · The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma · Persbericht

7 september 2022 · CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference · Persbericht

Mijn selecties